DEA Telemedicine Flexibilities Extended Through 2026: What Telehealth Operators Need to Know

On December 31, 2025, the DEA and HHS issued a fourth temporary extension of COVID-era telemedicine flexibilities, allowing DEA-registered practitioners to prescribe Schedule II–V controlled substances via telemedicine without a prior in-person exam, if all regulatory conditions are met. The extension runs January 1 through December 31, 2026, buying another year while a permanent framework is finalized.

For telehealth operators, this is one of the most consequential regulatory dates on the calendar — and one of the most misunderstood. The flexibility is real, it is federal, and it keeps a large swath of telemedicine prescribing legal that would otherwise snap back to a 2008 statute written before modern telehealth existed. But it is temporary, it is conditional, and it does not do half of what operators assume it does. Here is the accurate picture.

---

What Did the DEA Actually Extend for 2026?

The DEA and HHS extended the COVID-19 telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026. Published in the Federal Register on December 31, 2025, this "Fourth Temporary Extension" is effective January 1, 2026 and permits a DEA-registered practitioner to prescribe Schedule II–V controlled substances via telemedicine without a prior in-person evaluation, when conditions are met.

According to the DEA, during the period May 12, 2023 through December 31, 2026, a registered practitioner is authorized to prescribe schedule II–V controlled substances via telemedicine to a patient without having conducted an in-person medical evaluation, provided all conditions in the regulation are satisfied. The rule amends portions of 21 CFR 1307.41 and 42 CFR 12.1 for the extension period. In its announcement, the agency framed the extension as necessary to "ensure continued access to care" while it finalizes a permanent approach.

Two related final rules — one expanding buprenorphine treatment via telemedicine, one on continuity of care for Veterans Affairs patients — took effect December 31, 2025, sitting alongside the temporary extension.

---

Why Do These Flexibilities Exist in the First Place?

They exist because the default rule is stricter. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person medical evaluation before a practitioner can prescribe a controlled substance over the internet. The COVID-19 public health emergency triggered an exception; the DEA's temporary extensions keep that exception alive.

When the COVID-19 public health emergency was declared in 2020, HHS and the DEA waived the in-person requirement so patients could keep getting medications — including controlled substances for pain, ADHD, opioid use disorder, and hormone therapy — without an office visit. The public health emergency ended on May 11, 2023, but the DEA recognized that abruptly reimposing the in-person mandate would strand millions of established patients. Rather than let the flexibility lapse, the agency has issued a series of temporary extensions. The 2026 rule is the fourth.

This history matters for one reason: the flexibility is a bridge, not a destination. The DEA has repeatedly signaled its intent to finalize a permanent telemedicine framework — including a long-promised "special registration for telemedicine" contemplated by the original statute — but that permanent rule has not been finalized. Building a business on a bridge means knowing where the bridge ends.

---

What the Extension Does Not Do

This is where operators get into trouble. The federal flexibility is necessary but not sufficient. Three things it does not do:

• It does not override state law. Telemedicine prescribing is regulated by both the federal government and every state a patient sits in. Some states impose their own in-person requirements, prescribing limits, or telehealth-specific rules that are stricter than the federal baseline. The DEA extension does not preempt them.
• It does not remove clinical responsibility. A practitioner still owns every prescribing decision. The flexibility removes a procedural prerequisite; it does not lower the standard of care or shift liability.
• It does not make every controlled substance a good telehealth product. Legal to prescribe is not the same as prudent to build a category on. Schedule II stimulants and opioids carry heightened scrutiny regardless of the flexibility.

We go deeper on the interaction between federal and state rules in the compliance requirements every telehealth operator carries, and on the Ryan Haight baseline itself in how the Ryan Haight Act governs online controlled-substance prescribing.

---

How Does This Affect TRT and Hormone Clinics?

Directly. Testosterone is a Schedule III controlled substance under the Controlled Substances Act, so any clinic prescribing testosterone for TRT is operating inside the DEA telemedicine framework — the same one the 2026 extension governs. Hormone operators cannot treat this as someone else's compliance problem.

If you run or plan to run a virtual TRT clinic, the 2026 extension is what currently permits your prescribers to initiate testosterone therapy via telemedicine without an in-person visit, subject to conditions and state law. That is a meaningful enabler — and a meaningful dependency. We walk through the operational side in opening a virtual TRT clinic, and the state-coverage side in building a 50-state prescriber network.

The practical takeaway for hormone operators: keep prescriber DEA registrations current, keep provider approval and documentation airtight for every order, and track the December 31, 2026 horizon as a real planning date, not a distant abstraction.

---

The Extension Timeline at a Glance

Milestone	Date	What changed
Ryan Haight Act enacted	2008	In-person exam generally required before online controlled-substance prescribing
COVID-19 PHE flexibility begins	2020	In-person requirement waived for telemedicine
COVID-19 PHE ends	May 11, 2023	Flexibility continued via temporary DEA rules rather than lapsing
Fourth Temporary Extension published	Dec 31, 2025	Flexibility extended through the 2026 calendar year
Extension in effect	Jan 1 – Dec 31, 2026	Schedule II–V telemedicine prescribing permitted, conditions apply
Permanent framework	Not finalized	Special registration and durable rules still pending

The pattern is unmistakable: a series of one-year reprieves, each issued near the deadline of the last. An operator who assumes the next extension is automatic is making a bet the DEA has not promised to honor.

---

What Should Operators Do About It?

Treat the flexibility as a resource to use carefully, not a foundation to bet the company on. Five concrete steps:

1. Know which of your products are controlled. Map every SKU to its schedule. If nothing you sell is controlled, the DEA clock does not gate your core business — a genuine advantage.
2. Keep provider approval and documentation flawless. The flexibility lowers a procedural bar; it raises the importance of clean records showing a licensed provider made a real clinical decision on every order.
3. Track state law per prescriber and per patient state. Federal permission plus a state violation still equals a violation.
4. Watch for the permanent rule. When the DEA finalizes a durable framework — including any special registration — the conditions may change materially. Do not be caught flat.
5. Diversify off the dependency where you can. An operator whose entire catalog rests on a temporary federal exception is carrying a single point of failure with a printed expiration date.

That last point is where infrastructure choices meet compliance strategy. The reason non-controlled 503A compounding remains the steadier default for a new operator is precisely that it sidesteps this clock. A category built on non-controlled compounds does not live or die by the next Federal Register notice. Controlled substances can absolutely be part of a mature, well-run clinic — but they should be a deliberate addition, made with counsel, not the load-bearing wall of a business that is still finding its footing.

---

Key Takeaways

• The DEA's fourth temporary extension keeps telemedicine controlled-substance prescribing flexibilities in effect from January 1 through December 31, 2026.
• It permits DEA-registered practitioners to prescribe Schedule II–V controlled substances via telemedicine without a prior in-person evaluation — but only when every underlying condition and state-law requirement is also met.
• This is a temporary bridge. A durable framework, including a long-promised special registration for telemedicine, has not been finalized.
• The flexibility is federal; stricter state telemedicine and prescribing laws still apply on top.
• Testosterone is a Schedule III controlled substance, so DEA rules directly affect TRT and hormone clinics.
• Non-controlled 503A compounding avoids this regulatory clock entirely, which is why it remains the steadier default for a new operator.

---

Frequently Asked Questions

How long do the DEA telemedicine flexibilities last?

Through December 31, 2026. On December 31, 2025, the DEA and HHS published a fourth temporary extension in the Federal Register, keeping the COVID-era flexibilities in effect for the full 2026 calendar year. It is a temporary rule — the fourth of its kind — issued to prevent a lapse while the agencies work toward a permanent telemedicine prescribing framework. Operators should not assume it becomes permanent automatically.

Can I prescribe controlled substances via telehealth in 2026 without an in-person visit?

Under the extension, a DEA-registered practitioner may prescribe Schedule II–V controlled substances via telemedicine without a prior in-person evaluation, provided all conditions in the rule and all applicable state laws are met. The federal flexibility does not override stricter state requirements, and it does not remove the practitioner's independent clinical and legal responsibility for each prescription.

Does the DEA extension affect testosterone and TRT clinics?

Yes. Testosterone is a Schedule III controlled substance under the Controlled Substances Act, so TRT prescribing sits squarely inside the DEA telemedicine framework. Operators launching hormone clinics that prescribe testosterone need to track both the federal flexibility timeline and their prescribers' state rules. Categories built on non-controlled compounds are not exposed to this particular clock.

What is the Ryan Haight Act and how does it relate to this?

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person medical evaluation before a practitioner can prescribe a controlled substance online. The COVID-19 public health emergency triggered an exception to that in-person requirement, and the DEA's temporary extensions — including the 2026 one — keep that exception alive while a permanent telemedicine pathway is developed.

What should operators do to prepare for the end of 2026?

Plan for uncertainty. Build categories that do not depend on the flexibility where you can, keep provider approval and documentation airtight, track state-by-state prescribing rules, and watch for the DEA's permanent rulemaking. An operator whose entire model rests on a temporary federal exception is carrying a regulatory single point of failure with a known expiration date.

---

neolife is the fulfillment rail that sits on top of the pharmacy you already use, with a licensed provider approving every order and a retrievable approval record behind each one — the documentation discipline that matters most when compliance rules are in flux. If you are building in a category touched by the DEA timeline and want infrastructure that keeps your records audit-ready, talk to us. This post is educational and not legal advice; confirm specifics with your own healthcare counsel and prescribers' state boards.